Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 20:48:101458.
doi: 10.1016/j.eclinm.2022.101458. eCollection 2022 Jun.

The global burden of sore throat and group A Streptococcus pharyngitis: A systematic review and meta-analysis

Kate M Miller  1 , Jonathan R Carapetis  1   2 , Chris A Van Beneden  3 , Daniel Cadarette  4 , Jessica N Daw  1 , Hannah C Moore  1 , David E Bloom  4 , Jeffrey W Cannon  1   4
Affiliations

The global burden of sore throat and group A Streptococcus pharyngitis: A systematic review and meta-analysis

Kate M Miller et al. EClinicalMedicine. .

Abstract

Background: Contemporary data for the global burden of sore throat and group A Streptococcus (Strep A) pharyngitis are required to understand the frequency of disease and develop value propositions for Strep A vaccines.

Methods: We used Clarivate Analytics' Web of Science platform to search WoS core collection, PubMed, Medline, data citation index, KCI-Korean Journal Database, Russian Science Citation Index, and the SciELO Citation Index for articles published between Jan 1, 2000, and Feb 15, 2021, from any country and in any language. The risk of bias was assessed using the JBI critical appraisal checklist. We used random-effects meta-analyses to pool sore throat and Strep A sore throat incidence rates from community-based studies. Our study was registered with PROSPERO (CRD42020181103).

Findings: Of 5,529 articles identified by the search strategy, 26 studies met the inclusion criteria, but only two included data to determine incidence among adults. The pooled incidence rate, calculated for children only, was 82.2 episodes per 100 child-years (95% CI 25.2-286.3, I2 = 100%) for sore throat (7 studies; 7,964 person years) and 22.1 episodes per 100 child-years (95% CI 14.7-33.1, I2 = 98%) for Strep A sore throat (9 studies; 15,696 person years). The pooled cumulative incidence rate of sore throat from five studies was 31.9 per 100 children. There was significant methodological and statistical heterogeneity among studies, and five of 26 studies had a risk of bias score less than five (range: nine [maximum score] to one).

Interpretation: Strep A sore throat has a considerable global burden. However, methodologically standardised studies are required to quantify that burden, analyse differences in rates between populations, and evaluate the likely impact of future Strep A vaccines.

Funding: This study was funded by Wellcome Trust 215,490/Z/19/Z.

Keywords: Burden; Incidence; Pharyngitis; Sore throat; Streptococcus; Surveillance.

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Figures

Figure 1
Figure 1
PRISMA flowchart.
Figure 2
Figure 2
Countries in which studies described the incidence of sore throat or Strep A sore throat.
Figure 3
Figure 3
Incidence rates of sore throat among children.
Figure 4
Figure 4
Pooled incidence rate of Strep A sore throat for children.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lozano R., Naghavi M., Foreman K., et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380:2095–2128. - PMC - PubMed
    1. Carapetis J.R., Steer A.C., Mulholland E.K., Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685–694. - PubMed
    1. Beaton A., Kamalembo F.B., Dale J., et al. The American heart association's call to action for reducing the global burden of rheumatic heart disease: a policy statement from the American heart association. Circulation. 2020;142(20):e358–e368. - PubMed
    1. Vekemans J., Hasso-Agopsowicz M., Kang G., et al. Leveraging vaccines to reduce antibiotic use and prevent antimicrobial resistance: a world health organization action framework. Clin Infect Dis. 2021;73:e1011–e1017. - PMC - PubMed
    1. Vekemans J., Gouvea-Reis F., Kim J.H., et al. The path to group A streptococcus vaccines: world health organization research and development technology roadmap and preferred product characteristics. Clin Infect Dis. 2019;69(5):877–883. - PMC - PubMed

LinkOut - more resources